Progressive Supranuclear Palsy - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 71 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Progressive Supranuclear Palsy - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Progressive Supranuclear Palsy - Pipeline Review, H1 2016', provides an overview of the Progressive Supranuclear Palsy pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Progressive Supranuclear Palsy , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Progressive Supranuclear Palsy and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Progressive Supranuclear Palsy 
- The report reviews pipeline therapeutics for Progressive Supranuclear Palsy by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Progressive Supranuclear Palsy therapeutics and enlists all their major and minor projects
- The report assesses Progressive Supranuclear Palsy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Progressive Supranuclear Palsy 

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Progressive Supranuclear Palsy 
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Progressive Supranuclear Palsy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Progressive Supranuclear Palsy Overview 7
Therapeutics Development 8
Pipeline Products for Progressive Supranuclear Palsy - Overview 8
Progressive Supranuclear Palsy - Therapeutics under Development by Companies 9
Progressive Supranuclear Palsy - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Progressive Supranuclear Palsy - Products under Development by Companies 13
Progressive Supranuclear Palsy - Companies Involved in Therapeutics Development 14
AB Science SA 14
AbbVie Inc. 15
AlzProtect SAS 16
Cortice Biosciences, Inc. 17
Merck & Co., Inc. 18
Otsuka Holdings Co., Ltd. 19
Prana Biotechnology Limited 20
Sellas Inc. 21
TauRx Therapeutics Ltd. 22
Progressive Supranuclear Palsy - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
ABBV-8E12 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
ASN-561 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
AVP-786 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
AZP-2006 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
BMS-986168 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
DC-TAB - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
DPC-016 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
masitinib - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
MK-8719 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
PBT-434 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Small Molecules for Progressive Supranuclear Palsy - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
TPI-287 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
TRx-0237 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
zolpidem tartrate - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
Progressive Supranuclear Palsy - Dormant Projects 66
Progressive Supranuclear Palsy - Product Development Milestones 67
Featured News & Press Releases 67
Jul 17, 2015: C2N And Abbvie Announce FDA Orphan Drug Designation Of C2N-8E12 (ABBV-8E12) For The Treatment Of Progressive Supranuclear Palsy 67
Jul 07, 2014: Cortice Announces Enrollment of a Phase 1 Clinical Trial Evaluating TPI 287 in Rare Tauopathy Diseases 67
Dec 10, 2013: Potential Treatment for Parkinson's & Parkinson-Like Diseases with Zolpidem: Sellas Life Sciences Group Holds Global Development & Marketing Rights 68
Appendix 70
Methodology 70
Coverage 70
Secondary Research 70
Primary Research 70
Expert Panel Validation 70
Contact Us 70
Disclaimer 71

List of Tables

Number of Products under Development for Progressive Supranuclear Palsy, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Development, H1 2016 12
Products under Development by Companies, H1 2016 13
Progressive Supranuclear Palsy - Pipeline by AB Science SA, H1 2016 14
Progressive Supranuclear Palsy - Pipeline by AbbVie Inc., H1 2016 15
Progressive Supranuclear Palsy - Pipeline by AlzProtect SAS, H1 2016 16
Progressive Supranuclear Palsy - Pipeline by Cortice Biosciences, Inc., H1 2016 17
Progressive Supranuclear Palsy - Pipeline by Merck & Co., Inc., H1 2016 18
Progressive Supranuclear Palsy - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 19
Progressive Supranuclear Palsy - Pipeline by Prana Biotechnology Limited, H1 2016 20
Progressive Supranuclear Palsy - Pipeline by Sellas Inc., H1 2016 21
Progressive Supranuclear Palsy - Pipeline by TauRx Therapeutics Ltd., H1 2016 22
Assessment by Monotherapy Products, H1 2016 23
Number of Products by Stage and Target, H1 2016 25
Number of Products by Stage and Mechanism of Action, H1 2016 27
Number of Products by Stage and Route of Administration, H1 2016 29
Number of Products by Stage and Molecule Type, H1 2016 31
Progressive Supranuclear Palsy - Dormant Projects, H1 2016 66